^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | RAF709 (BRAF inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
Excerpt:
Figure 3. RAF709 inhibits oncogenic signaling and proliferation in tumor cells with BRAF, NRAS, and KRAS mutations, with minimal paradoxical activation.
DOI:
10.1158/0008-5472.CAN-17-2033
